• Toremifene in Prostate Cancer: Applied Workflows & Key Innov

  2026-04-13

  Toremifene, a potent selective estrogen-receptor modulator, empowers researchers to dissect hormone-dependent cancer pathways and calcium signaling in advanced prostate cancer models. This article translates cutting-edge findings on the TSPAN18-STIM1 axis into actionable protocols, troubleshooting guidance, and strategic advantages for hormone-responsive cancer research.

• Rotenone as a Mitochondrial Complex I Inhibitor: Advanced Wo

  2026-04-13

  Rotenone serves as a benchmark mitochondrial Complex I inhibitor for modeling mitochondrial dysfunction, autophagy, and neurodegenerative disease pathways. This guide details evidence-driven protocols, troubleshooting strategies, and key innovations that enable precise, reproducible outcomes in advanced cellular and animal research.

• BMP4-GPX4 Axis Mitigates Ferroptosis in Glaucoma Models

  2026-04-12

  This study demonstrates that activation of the BMP4-GPX4 pathway reduces ferroptosis and enhances differentiation of retinal stem cells (RSCs) into retinal ganglion cells (RGCs) following transplantation in a mouse model of glaucoma with high intraocular pressure. The findings provide a mechanistic basis for targeting ferroptosis in neurodegenerative disease models and inform experimental approaches for evaluating stem cell-based neuroprotection.

• RCN2 Drives ESCC Metastasis and Cisplatin Resistance via PI3

  2026-04-12

  This study identifies Reticulocalbin 2 (RCN2) as a novel facilitator of metastasis and cisplatin resistance in esophageal squamous cell carcinoma (ESCC) through UBR5-mediated degradation of PPP2CA, activating the PI3K-AKT signaling pathway. Targeting RCN2 or its downstream effectors may offer new strategies to combat ESCC progression and therapy resistance.

• Amikacin (BAY416651): Protocols & Best Practices in Resistan

  2026-04-11

  Amikacin (BAY416651) stands out as a robust tool in antibiotic resistance research, especially for studies on carbapenem-resistant Enterobacter cloacae and Klebsiella pneumoniae. Its resistance to most modifying enzymes and excellent aqueous solubility streamline reproducibility and troubleshooting in multidrug-resistant bacterial workflows.

• Epalrestat: Optimizing Aldose Reductase Inhibitor Workflows

  2026-04-11

  Epalrestat stands at the forefront of oxidative stress and neurodegenerative disease research, uniquely enabling mechanistic and translational studies through its dual action on the polyol pathway and KEAP1/Nrf2 axis. This guide details robust protocol strategies and troubleshooting insights to maximize reproducibility, drawing from the latest neuroprotection breakthroughs and high-purity sourcing from APExBIO.

• Isopentyl Acetate (C7H14O2): Protocols and Workflow Guidance

  2026-04-10

  Isopentyl acetate (SKU B7890) is an ester compound widely used in biochemical research where water-insoluble esters are required. Its high purity and stability make it suitable for reproducible experimental workflows, provided storage and solubilization protocols are carefully followed. This product is not intended for diagnostic or medical applications and should not be used outside research settings.

• DMXAA (Vadimezan): Unraveling Vascular Disruption and Imm...

  2026-04-10

  Explore the multifaceted role of DMXAA (Vadimezan) as a vascular disrupting agent for cancer research, with unparalleled insight into its dual action on tumor vasculature and immune modulation. This article provides an advanced perspective on DMXAA’s mechanisms, leveraging the latest findings in STING-JAK1 signaling and tumor microenvironment normalization.

• Unleashing the Potential of Omeprazole in Translational G...

  2026-04-09

  This thought-leadership article explores the frontiers of gastric acid secretion research, antiulcer drug development, and the emerging intersections with neuroinflammation and the gut–liver–brain axis. It offers a mechanistic deep dive into Omeprazole (3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide), articulates its competitive and translational advantages, and delivers actionable guidance for researchers seeking to advance the fields of proton pump inhibition and gastrointestinal pharmacology. Integrating fresh evidence from neuroinflammation models and building upon the APExBIO knowledge base, the article challenges traditional paradigms, fostering innovative experimental design and clinical translation.

• YC-1: Soluble Guanylyl Cyclase Activator & HIF-1α Inhibit...

  2026-04-08

  YC-1 (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol is a potent soluble guanylyl cyclase activator and HIF-1α inhibitor, widely used in cancer and hypoxia signaling research. Its dual mechanism enables precise interrogation of tumor angiogenesis and apoptosis with reproducible results. APExBIO provides this compound at high purity for advanced experimental workflows.

• Palomid 529 (P529): Beyond Oncology—A Systems Approach to...

  2026-04-08

  Explore the multifaceted potential of Palomid 529 (P529) as a PI3K/Akt/mTOR inhibitor in cancer research and neural stem cell biology. This article offers a systems-level analysis, integrating new mechanistic insights and translational strategies for advanced research.

• Mifepristone (RU486): Progesterone Receptor Antagonist fo...

  2026-04-07

  Mifepristone (RU486) from APExBIO delivers robust, cell-permeable antagonism of progesterone and glucocorticoid receptors, empowering translational breakthroughs in oncology and reproductive biology. This guide reveals optimized workflows, advanced troubleshooting, and strategic applications for harnessing Mifepristone’s full experimental potential.

• Deferoxamine Mesylate: Mechanistic Leverage and Strategic...

  2026-04-07

  This thought-leadership article explores the strategic application and mechanistic depth of Deferoxamine mesylate in translational research. We unravel its role as a precision iron-chelating agent, a hypoxia mimetic, and a modulator of ferroptosis, providing actionable insights for oncology, regenerative medicine, and organ transplantation. By integrating landmark findings—such as the recent elucidation of ferroptosis in mitochondrial disease—and referencing advanced workflows, we establish a new paradigm for leveraging Deferoxamine mesylate in experimental and preclinical settings.

• Beyond Apoptosis: Mechanistic Insight and Strategic Guida...

  2026-04-06

  This thought-leadership article explores Erastin’s transformative role as a small molecule ferroptosis inducer, highlights mechanistic advances in iron-dependent, non-apoptotic cell death targeting RAS/BRAF-mutant cancers, and delivers actionable strategies for translational researchers. Integrating new evidence from plant-pathogen interactions, the piece reframes ferroptosis as a universal biological phenomenon and positions Erastin as an indispensable tool for advanced cancer biology, oxidative stress assays, and therapeutic innovation.

• Catalpol: Natural Iridoid Glycoside for Multi-Pathway Neu...

  2026-04-06

  Catalpol, a natural iridoid glycoside, is a validated multi-target research tool for neuroprotection, osteoporosis, and translational disease models. As an NF-κB, EphA2/FAK/Src, and NLRP3 inflammasome inhibitor, and TrkB receptor activator, Catalpol enables rigorous pathway interrogation and reproducible animal modeling. This dossier provides atomic, evidence-backed facts for the deployment of Catalpol (SKU N1352, APExBIO) in preclinical workflows.

16442 records 1/1097 page Next 12345 下5页 Last page